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procedural similarity, a blinded catch-up validation study for skin irritation according toOECD Performance Stan-
dards (PS)was conducted in three laboratories to promote regulatory acceptance,with OS-REpmodels produced
at a single production site only.While overall sensitivity and predictive capacitymet the PS requirements, overall
speciﬁcity was only 57%. A thorough analysis of the test results led to the assumption that some of the false-pos-
itive classiﬁcations could have been evoked by volatile skin-irritating chemicals tested in the same culture plate
as the non-irritants falsely predicted as irritants.With GC/MS and biological approaches the cross-contamination
effect was conﬁrmed and the experimental set-up adapted accordingly. Retesting of the affected chemicals with
the improved experimental set-up and otherwise identical protocol resulted in correct classiﬁcations as non-ir-
ritants. Taking these re-test results into account, 93% overall sensitivity, 70% speciﬁcity and 82% accuracy was
achieved, which is in accordancewith the OECD PS. A sufﬁcient reliability of themethodwas indicated by awith-
in-laboratory-reproducibility of 85–95% and a between-laboratory-reproducibility of 90%.
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. This is an open access article underproducts must undergo an extensive toxicological assessment. Human
skin is the ﬁrst contact site for numerous chemicals. Thus in vitro test
methods, which aim at reliably identifying reactions of irritating
chemicals with dermal tissue, have been developed. Moreover, since
2009 only in vitro tests are still allowed in the European Union to dem-
onstrate the safety of new cosmetic ingredients for the skin (EU, 2009).
During the last decade three-dimensional skin models which closely
mimic native human epidermis in respect of tissue architecture and
physiology have been recognized as suitable tools to test a wide variety
of chemicals (de Wever et al., 2013). However, validation and accep-
tance by organisations like EURL-ECVAM and the OECD are mandatory
for any in vitro test method before being used in the framework of the
EU Cosmetics Regulation (EC) No. 1223/2009 (EU, 2009).
The latest version of the OECD TG 439 lists 4 commercially available
in vitro test methods for skin irritation testing, based on different epi-
dermal equivalents, which have undergone formal validation: the
EpiSkin™ and EpiDerm™models, the Skin Ethic™ RHE and the LabCyte
EPI-MODEL24SIT (Spielmann et al., 2007; EURL-ECVAM, 2008, 2009a,
2009b; Katoh et al., 2009; Kojima et al., 2012, 2014; OECD, 2011, 2015a).
Some other pure epidermal models – Sterlab Epidermis, StratiCELL
RHE, epiCS (formerly EST-1000), and KeraSkin™-VM have entered thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tion study for skin irritation testing is still missing (http://www.
sterlab.com; http://www.straticell.com; http://reconstructed-human-
epidermis.com, Jung et al., 2014).
All human epidermal equivalents mentioned above have one aspect
in common: They are produced at the respective company's production
site only and partly based on conﬁdential and legally protected proto-
cols. For the user of one of the accepted skin irritation tests the advan-
tage of working with standardized and quality-approved tissue
equivalents from one supplier must be balanced against tissue costs.
In addition, several non-European countries have set up high customs
barriers regarding the import of living human tissues, which hinder in-
terested laboratories in these countries from using the tissue equiva-
lents commercially produced abroad. Hence, these countries are in
part cut off from innovation in the framework of in vitro alternative
methods. Another disadvantage of using commercial skin models is its
possible quality loss after shipment over longer periods of times and
distances. In order to circumvent this restricted situation on the skin
modelmarket we decided to develop an in vitro test method for skin ir-
ritation assessment based on an open source reconstructed epidermis
(OS-REp). The Open Source Conceptwas introduced ﬁrst in information
technology (IT) in the early 1980s with LINUX as the most prominent
example for free and open source software (see e.g. Nicolosi and
Ruivenkamp, 2012).
What has become a story of success in IT is still largely unknown in
the ﬁeld of alternatives to animal testing. Until today, nearly all regula-
tory accepted and/or scientiﬁcally valid in vitro test methods based on
3D tissue models depend on a few companies only, which produce
anddistribute their tissue equivalents for commercial purposes. This sit-
uation is illustrated by the circumstance that the 4 epidermal models
which are currently included in the OECD test guideline 439 are pro-
duced by 3 companies only.
By introducing the open source concept into the framework of in
vitro testing for regulatory purposes we intend to accelerate the devel-
opment, acceptance and dissemination of innovative alternatives to an-
imal testing worldwide. Our concept means that all protocols for cell
isolation and proliferation, for the construction of the 3-dimensional tis-
sue equivalent and the performance of the irritation test are herewith
made publicly availablewithout any legal restrictions due to intellectual
property or licenses. Thus the OS-REp model culture is intended to be
established by any potential user at any laboratory worldwide to be
used either for skin irritation tests according to the protocol depicted
in this paper or for other purposes. The open source concept will even-
tually lead to greater independence from commercial suppliers, cost re-
duction for the users and a suitable strategy to circumvent trade hurdles
for living tissue models in several countries, e.g. in India and Brasil.
However, it does not exclude the option to start a business with the
newly-developed methods.
The OS-REp model is based on a protocol for epidermal equivalent
culture originally developed and published by Poumay et al. (2004)
for the unrestricted use in any laboratory. It consists of normal,
human-derived epidermal keratinocytes, which have been cultured at
the air-liquid interface (ALI) to form a multilayered, highly differentiat-
ed epidermal tissue. The tissue exhibits organized basal, spinous and
granular layers, and a multi-layered stratum corneum and thus closely
mimics native human epidermis. Based on the PS and taking the speciﬁc
tissue properties of the OS-REp into account, a protocol for testing the
skin-irritating potential of topically applied chemicals was developed.
However, in order to gain regulatory acceptance as alternative method
its reliability and high predictive capacitymust be proven in a validation
process, generally consisting of a pre-validation study followed by a
multicentric validation study. Because of the structural, mechanistic
and procedural similarity of the OS-REpmodel and the OS-REp SIT pro-
tocol with already accepted testmethods, the acceptance process can be
short-cut by following the Performance Standards for in vitro Skin Irri-
tation Testing (OECD, 2015b).The OS-REp catch-up validation study was conducted in a two-tier
approach. In the ﬁrst phase (Phase I), which is the subject of this
paper, robustness and predictive capacity of the OS-REp skin irritation
testwere assessed in linewith the OECD Performance Standards in 3 in-
dependent laboratories. All OS-REpmodels used in this studywere pro-
duced exclusively at the developer's laboratory and subsequently
shipped to the validation partners. This strategy enabled us to focus
the analysis of the study results exclusively on the design of the SIT
without being jeopardized by possible variations regarding tissue qual-
ity and properties of OS-REp models cultured at different sites.
To complete the catch-up validation study under open source condi-
tions, a second study phase (Phase II) was initiated, where it was man-
datory for the study partners to produce the OS-REp models for skin
irritation testing by themselves, including keratinocyte isolation from
human donors and selection of the best suited cell lots for OS-REp pro-
duction. The results of phase II study will be reported in a second publi-
cation in this journal (Groeber et al., 2016-in this volume).
In this paper we present the results of the ﬁrst phase of the OS-REp
SIT catch-up validation study, independently conducted in 3 laborato-
ries and in accordance with the OECD Performance Standards for in
vitro skin irritation testing (2015b). Sensitivity and accuracy matched
the PS thresholds, whereas speciﬁcity was clearly below the threshold
of 70%. Those test data which led to the misclassiﬁcation of non-irritant
reference chemicals as irritants were retrospectively analyzed. We hy-
pothesized that the volatile fractions of skin-irritating reference
chemicals had damaged those tissues which had been tested in parallel
with the non-irritating chemicals in the same culture plate. Using gas
chromatography/mass spectroscopy techniques, the damaging effect
of volatile irritating chemicals, namely heptanal and cyclamen alde-
hyde, on the OS-REp equivalents was conﬁrmed, which subsequently
resulted in an optimized testing protocol. Based on the optimized proto-
col which prevented any kind of cross-contamination, the previously
misclassiﬁed chemicals were re-tested on the OS-REp models. Taking
the re-test results into account, speciﬁcity and accuracy now both
matched the PS.
In addition to the test results this paper provides detailed protocols
which will allow trained researchers to establish reconstructed epider-
mal models and to conduct skin irritation testing under open source
conditions independently from commercial suppliers and country.
With this approachwe contributeworldwide to the principles of reﬁne-
ment, reduction and replacement (3R) of animal experiments (Russel
and Burch, 1959).
2. Materials & methods
2.1. Materials
If not indicated otherwise, all chemicals were purchased from
Sigma-Aldrich, Germany. EpiLife® medium, Human Keratinocyte
Growth Supplement (HKGS) supplement, penicillin/streptomycin solu-
tion and trypsin/EDTA solution were purchased from Life Technologies
GmbH, Germany. Accutase® was delivered by PAA, Germany. The cell
strainers were from BD Falcon, USA, the co-culture inserts from Merck
Millipore, Germany (Millicell-PVF, 0.4 μmpore size, 12mm outer insert
diameter, membrane area≈0.63 cm2). Fetal Clone II serum was pur-
chased from Thermo Scientiﬁc, Germany, the fetal calf serum from
Biochrom GmbH, Germany.
2.2. Culture media
Transport medium (TP medium): Dulbecco's Modiﬁed Eagle Medi-
um (DMEM, incl. 4.5% Glucose, GlutaMAX™, Pyruvate) was supple-
mented with L-ascorbic acid 2-phosphate (1 mM), penicillin/
streptomycin (100UI/mLand 100 μg/mL) and fetal calf serum(10% v/v).
Keratinocyte medium for freshly isolated keratinocytes (passage 0)
and feeder cell culture (K medium): A blend of DMEM and Ham's F-12
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(10−1 nM), tri-iodo thyronin (5 μg/mL), L-ascorbic acid 2-phosphate
(1 mM), penicillin (100 UI/mL)/streptomycin (100 μg/mL), re-
combinant human epidermal growth factor (10 ng/mL), adenin
(24.3 μg/mL), hydrocortisone (0.4 μg/mL), bovine insulin (0.12 U/mL)
and Fetal Clone II (10% v/v).
Primary keratinocytes in all passages higher than P0 were cultured
in EpiLife® Basal medium supplemented with 1% HKGS consisting of
bovine pituitary extract (0.2% v/v end concentration), recombinant
human insulin-like growth factor-I (1 μg/mL), hydrocortisone
(0.18 μg/mL), bovine transferrin (5 μg/mL) and human epidermal
growth factor (0.2 ng/mL) andwith penicillin (100U/mL)/streptomycin
(100 μg/mL). During the submersed phase theOS-REpmodelswere cul-
tured with EpiLife® Submerse medium supplemented with 1% HKGS,
Penicillin (100 U/mL)/Streptomycin (100 μg/mL), and CaCl2 solution
(1.5mMﬁnal concentration). After being lifted to the air liquid interface
(ALI), themodels were culturedwith EpiLife® ALImedium consisting of
EpiLife® Submerse medium supplemented with ascorbic acid phos-
phate solution (73 μg/mL end concentration) and keratinocyte growth
factor (KGF, 10 ng/mL).
3. Epidermal model culture
3.1. Origin and isolation of keratinocytes
The OS-REp models were produced according to a protocol pub-
lished by Poumay et al. (2004) with some modiﬁcations. Keratinocytes
were isolated from juvenile foreskin biopsies of boys not older than
7 years. Use of the foreskin tissues after circumcision was in accordance
with German law and took place only after informedwritten consent by
the parents.
The enzymatic separation of epidermis and dermis started within
24 h after surgery. The biopsies were transported to the laboratory in
transport medium (TP medium). Adipose tissue and adhering blood
vessels were removed, and the biopsy was cut into small pieces of
approx. 5–8 mm lengths with a scalpel. The pieces were placed in a
petri dish with the epidermis facing upwards, followed by the addition
of thermolysin solution (500 μg/mL in 0.01 M HEPES buffer). The vol-
ume of thermolysinwas adjusted to a height of approx. half of the tissue
thickness without covering the epidermal surface. After incubation for
15–18 h at 4 °C the epidermis was removed from the underlying dermis
with tweezers, the dermis was discarded. The epidermal sheets were
transferred into 20 mL of a Trypsin-EDTA solution (0.05% trypsin in
0.2 g/L EDTA) and incubated for 20min at 37°. Repeated shaking during
the incubation period increased the dissociation success. The enzymatic
reaction was stopped with an equal volume of keratinocyte medium (K
medium), and the cells were isolated by repeated aspiration of the epi-
dermal pieces into and released from a 10 mL pipette. The cell suspen-
sion was applied onto a cell strainer (70 μm mesh size, BD Falcon,
USA), and the resulting suspension was centrifuged at 178 g to collect
the cells. The pellet was resuspended in 10 mL Kmedium, and after de-
termination of the cell number the keratinocytes were seeded into cell
culture ﬂasks (175 cm2 area) at a density of 2–4 × 106 cells per ﬂask.
In order to support optimal cell proliferation the keratinocytes were
grown on a feeder layer consisting of mitomycin C-inactivated human
skin ﬁbroblasts. The feeder cell culture was started in K medium 2–
3 days before keratinocyte isolation to enable proper medium condi-
tioning, and the keratinocytes were added without previous medium
change. The keratinocytes were then cultured at 37 °C and 5% (v/v)
CO2 in an incubator (passage 0). The ﬁrst medium exchange took
place 24 h after inoculation, followed by 2–3 exchanges per week, de-
pending on the growth rate. After having reached a conﬂuency degree
of approx. 75–80%, the keratinocytes were harvested. The culture was
rinsed with PBS w/o Ca2+ and Mg2+ (Invitrogen) once, and the cells
were detached by incubation with a Trypsin-EDTA solution for a maxi-
mum of 8 min. They were sedimented by subsequent centrifugation at178 g for 5 min. All P0 keratinocytes were immediately frozen at
−80 °C in keratinocyte medium supplemented with 10% (v/v) DMSO
at a cell density of 3 × 106 cells/mL and stored in liquid nitrogen until
needed.
In order to multiply the cell number, cryostored cells of P0 were
quickly thawed and seeded into large culture ﬂasks (175 cm2) at a den-
sity of 750,000 cells each in 25 mL of prewarmed EpiLife® Basal medi-
um. It is crucial for the culture process that for any passage higher
than P0 exclusively media based on EpiLife® without feeder cells must
be used. Culture medium was exchanged 3 times a week until the
culture had reached approx. 80–90% conﬂuency. Then the cells were
harvested with Accutase® (10 mL/culture ﬂask for 8–10 min) and
subsequently frozen in liquid nitrogen again (passage 1).
3.2. OS-REp model culture
For the OS-REp model production, keratinocytes of passage 3 were
needed. Thus, keratinocytes which had been cryopreserved at passage
1 were thawed, seeded into cell culture ﬂasks at a density of
750,000 cells/ﬂask and cultured with EpiLife® Basal medium until
~80–90% conﬂuency at 37 °C/5% CO2 (passage 2). Cells were harvested
with Accutase®, counted and seeded into Millicell co-culture inserts at
a seeding density of 315,000 cells (≈500,000 cells/cm2 membrane
area; passage 3). After 24 h culture under submersed conditions with
EpiLife® Submersemedium the cultures were lifted at the ALI by simul-
taneously discarding the culture medium from the inserts' inner cylin-
der and lowering the medium level in the culture vessel, e.g. a 6-well
plate or a petri dish, to the level of the insert membrane. At least
1.5 mL of medium per tissue model for 2 days is mandatory for the ALI
culture. The models were cultured at the ALI for 19 days with EpiLife®
ALI medium. Epidermal models whose surface did not dry at any time
during the ALI phase were discarded due to compromised terminal
differentiation.
4. Skin irritation test
4.1. Study design
The OS-REp skin irritation test catch-up validation study was con-
ducted according to the performance standards (PS) which had been
previously deﬁned by the EURL-ECVAM, later became an intergral part
of the OECD Test Guideline 439, and have been recently adopted as a
separate OECD PS Document (OECD, 2015b). The Reference Chemicals
were coded and distributed by ZEBET and the method was assessed in-
dependently in three laboratories comprising the lead laboratory
(Henkel, Germany) and two ‘naive’ laboratories (University Frankfurt,
Germany, and VITO NV, Belgium). Each laboratory tested the same set
of 20 coded reference chemicals (Table 1) under blinded conditions in
3–5 independent runs at different occasions (Fig. 1). In each run, each
test chemical was concurrently tested in three tissue replicates. In addi-
tion, for the set of test chemicals tested on that day three replicate tis-
sues were treated with the negative control agent (NC) and three
replicate tissues were treated with the positive control agent (PC).
Only test data which met all test acceptance criteria deﬁned in the
SOPwere considered valid and hence could be used in the data analysis.
However, in case of invalid data, amaximumof 5 repeats for a single test
chemical, or ﬁve repeats for a complete test runwere allowed. For qual-
ity control, experimental data were collected in Excel spreadsheets and
submitted to ZEBET/BfR for independent biostatistical analysis. To com-
plete these data with additional auditable information as required by
quality assurance systems like GLP or ISO 17025, for each testing day a
“method documentation sheet (MDS)” was used for recording all test
conditions other than the experimental test data. A ﬂowchart of the piv-
otal working steps for conducting the OS-REpmodel-based in vitro skin
irritation assay is depicted in Fig. 2.
Table 1
Reference chemicals for the skin irritation test and their respective code numbers. Given are the number and the name of the chemicals, the corresponding Chemical Abstracts Service
(CAS) registration number, and the codes of the blinded samples which were independently generated for each of the participating laboratories by ZEBET.
No. Chemical Name CAS Number GHS in vivo Code numbers
Henkel Univers. Frankfurt VITO
1 methyl stearate 112-61-8 No Cat. A242 B165 C050
2 di-n-propyl disulphide 629-19-6 Cat. 2 A169 B007 C123
3 hexyl salicylate 6259-76-3 No Cat. A252 B167 C116
4 heptanal 111-71-7 Cat. 2 A243 B045 C114
5 diethyl phthalate 84-66-2 No Cat. A063 B003 C106
6 heptyl butyrate 5870-93-9 No Cat. A039 B180 C177
7 1-bromohexane 111-25-1 Cat. 2 A295 B236 C251
8 naphthalene acetic acid 86-87-3 No Cat. A006 B119 C229
9 allyl phenoxy-acetate 7493-74-5 No Cat. A222 B238 C028
10 4-methyl-thio-benzaldehyde 3446-89-7 No Cat. A047 B008 C005
11 1-bromo-4-chlorobutane 6940-78-9 No Cat. A171 B027 C193
12 isopropanol 67-63-0 No Cat. A136 B234 C264
13 1-decanol 112-30-1 Cat. 2 A099 B239 C049
14 potassium hydroxide (5% aq.) 1310-58-3 Cat. 2 A187 B118 C031
15 1-methyl-3-phenylpiperazine 5271-27-2 Cat. 2 A122 B200 C011
16 2-chloromethyl-4-methoxy-3,5-dimethylpyridine HCl 86604-75-3 Cat. 2 A276 B096 C227
17 cinnamaldehyde 104-55-2 No Cat. A284 B223 C250
18 2-methyl-5-tert-butylthiophenol 7340-90-1 Cat. 2 A121 B078 C030
19 tetrachloroethylene 127-18-4 Cat. 2 A120 B248 C014
20 cyclamen aldehyde 103-95-7 Cat. 2 A210 B032 C257
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Prior to the substance testing, all tissuemodelswere transferred into
fresh prewarmed EpiLife® ALImedium. Themodels were then topically
exposed to the reference chemicals (see Table 1) for 35 min each. For
liquids, 25 μL were dispensed directly atop the tissue surface using a pi-
pette without touching the surface. If the liquid did not spread evenly
over the surface in the ﬁrst instance, it was gently taken up and dis-
pensed again with the pipette until spreading was achieved. For solids,
an equivalent of 25 μL (approx. 25 mg) was distributed evenly over
the tissue surface with a sharp application spoon. Then 25 μL of sterile
D-PBS was added in order to wet the surface of the test material and
to increase surface contact. In every test run each substancewas applied
to 3 tissue models.4.1.2. Controls
As negative control (NC) 25 μL of D-PBS was topically applied to the
tissuemodels and tested concurrentlywith the test chemicals. 25 μL of a
5% aqueous SDS solutionwasused as positive control (PC). All chemicalsFig. 1. Study design of the OS-REp SIT catch-up validation study according to the EURL-ECVAM
chemical to be tested. [Diagram adapted and amended from a previous version of the Performwere tested for their ability to reduceMTT in the absence of living cells.
No MTT reducer was observed within the set of reference chemicals.
4.1.3. Tissue viability assay
After the 35 min exposure period at room temperature the tissues
were thoroughly washed 8 times with 600 μL D-PBS each, dipped 5
times into 500 mL of D-PBS,and transferred to 6-well plates with
1.5 mL of fresh prewarmed EpiLife® ALI medium. After 42 h of post-ex-
posure incubation at 37 °C/5% CO2 the tissues were transferred to 24-
well plates containing 0.2 mL of fresh MTT solution (1 mg/mL in D-
PBS), where they remained for another 3 h. The blue formazan dye,
caused by intracellular metabolic MTT reduction, was extracted with
2 mL of 2-propanol each for 2 h at room temperature or overnight at
4 °C. The optical density of the extracted formazan solution was deter-
mined in a multiplate spectrophotometer at a single wavelength be-
tween 540 and 600 nm, depending on the ﬁlters available in the
respective laboratories. The relative tissue viability was calculated for
each tissue as the percentage of themean optical density of the negative
control, which was deﬁned as 100% viability.Performance Standards (OECD, 2014). NC: negative control; PC: positive control; Test X:
ance Standards for in vitro skin irritation testing; EURL-ECVAM, 2009c].
Fig. 2. Flowchart of the pivotal working steps in order to conduct the skin irritation assay.
TS: test substance; NC: negative control; PC: positive control; RT: room temperature. The
process is described in more detail in the respective Materials & methodssection.
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In order to get information about the barrier function of the OS-REp
models, an ET50 test was conducted with every OS-REp batch used in
this study. Brieﬂy, the tissues were topically treated with a 1% TRITON
X-100 solution, and tissue viability was assessed with the MTT assay
at deﬁned time intervals after the start of the incubation. The ET50 was
calculated as the respective point of time where overall tissue viability
had decreased to 50%.4.1.5. Data analysis
An EXCEL spreadsheet was developed at ZEBET for data submission
and analysis. It was password-protected and provided to the participat-
ing laboratories. At the end of the study the spreadsheets containing the
test data were returned to ZEBET for ﬁnal analysis. The analysis and
graphical representation of the data were performed in the R statistical
computing environment (R Development Core Team, 2010) in combi-
nation with the R lattice package (Sarkar, 2010).
Data analysis after cross-contamination tests and retesting were
conducted at the Henkel laboratory with the respective spreadsheet.
However, this analysis was conducted under unblinded conditions.The mean ODs of the blanks were calculated and subsequently
subtracted from the OD data of all other samples (ODTS, ODNC, ODPC).
For each sample the relative tissue viability in comparison to the NC
was calculated using the following formulae:
Relative viability TS %ð Þ ¼ ODTS=mean of ODNC½   100
Relative viability NC %ð Þ ¼ ODNC=mean of ODNC½   100
Relative viability PC %ð Þ ¼ ODPC=mean of ODNC½   100
with TS: test substance, NC: negative control and PC: positive control.
For each TS, NC and PC the mean relative viability of the three indi-
vidual tissues was calculated. These data were the basis for the subse-
quent substance classiﬁcation.
4.1.6. Acceptance criteria
Based on historical data the mean optical density (OD) at λ= 540–
600 nm for the NCs should be between 0.8 and 1.5 relative units. Mean
viability of the PCs should be below 10% of the NC. According to the Per-
formance Standards (OECD, 2015b) the standard deviations for tripli-
cate measurements within a run must be equal or smaller than 18%
(SD ≤ 18%) in order to become accepted as a valid run.
4.1.7. Prediction model
The prediction model (PM), i.e. the algorithm or rule for interpreta-
tion of the test data, is an integral part of any toxicological test method.
In the current study, we used the PM developed with the validated ref-
erence method: a test substance is classiﬁed as a skin irritant (GHS cat-
egory 2) if the mean relative tissue viability of the respective tissues is
≤50% (OECD, 2015b). If the relative tissue viability is N50%, the chemical
is considered a non-irritant (whichmay include “mild irritants, GHS cat-
egory 3).
5. Physico-chemical analysis of cross contamination
Four OS-REp models were placed in 4 adjacent wells of a 6-well
plate, where they were cultured with EpiLife® ALI medium. Two tissue
models were topically treated with 25 μL of the volatile test substance
each (donor models), whereas the surface of the other 2 models were
covered with 25 μL of D-PBS (receptor models). In addition, two co-cul-
ture inserts,ﬁlledwith Tenax-TA®60/80MESH (2,6-diphenylene-oxide
polymer resin; Buchem BV, The Netherlands), an adsorbent powder,
were placed in the 2 remaining wells of the 6-well plate (Fig. 3). After
test chemical application the 6-well plates were covered by a lid
which was removed only at the end of the respective exposure period
or for the necessaryworking steps according to the protocol, respective-
ly. The lid did not seal thewells individually, but allowed the diffusion of
volatile substances into all wells of the respective 6-well plate. After
35 min of incubation with the chemicals, the donor models were thor-
oughly washed with D-PBS and then incubated for another 24 or 42 h
under standard conditions. The D-PBS from the receptor models was
carefully aspirated after 35 min of incubation, followed by a post-treat-
ment incubation period of 42 h, too.
Tissueswere collected after 0, 15 and 35min of substance treatment,
followed by sampling after 24 and 42 h of post-treatment incubation.
Donor models were collected at 35 min only. At each indicated time
point tissue models were removed from the 6-well plates, transferred
to 20 mL glass vials and immediately frozen at−80 °C in order to ﬁx
them until they were used for GC/MS analysis. In addition to the tissue
models the respective culture media and the TENAX-ﬁlled inserts
were also collected for analysis. For each of the indicated sampling
time points an individual 6-well plate containing the respective number
of tissue models and TENAX probes was cultured.
Fig. 4. Tissue architecture of the open source reconstructed epidermis at day 19 of air-
liquid interface culture. The tissue model was formalin-ﬁxed, embedded in parafﬁn, cut
and stained with hematoxylin/eosin. s.b.: stratum basale; s.s.: stratum spinosum; s.g.:
stratum granulosum; s.c.: stratum corneum. The tissue model was prepared for
histology while still adhering to the polycarbonate (PC) insert membrane.
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Detection and quantiﬁcation of chemicals in the sampleswas carried
outwith gas chromatography, followed bymass spectroscopy (GC/MS).
Depending on the nature of the samples, different GC/MS processes
were used (Fig. 3).
The culturemediumwas analyzedwith the headspace GC/MSmeth-
od on a Perkin Elmer Headspace “HS40” and Perkin Elmer GC
“Autosystem XL” with an Agilent/J&W DB-5MS column (30 m,
0.25 mm internal diameter (ID), 1.00 μm ﬁlm thickness (FT)).
To analyze the compounds trapped in the TENAX adsorbent powder
thermal desorption GC/MS analysis was conducted on an Agilent GC
6890 andAgilentMSD5973Gerstel TDS2 (Thermal Desorption System),
using an Agilent/J&W DB-5MS column (30 m, 0.25 mm ID, 1.00 μm FT).
The tissue model samples were analyzed with the dynamic head-
space method, using the same Agilent system as above, but with a dif-
ferent Agilent/J&W DB-5MS column (25 m, 0.20 mm ID, 0.33 μm FT).
7. Histology
OS-REpmodelswere cut out of the insertswith the insertmembrane
still adhering to the tissue, ﬁxed in 4% buffered formaldehyde solution
(Roti-Histoﬁx, Roth, Germany), and embedded in parafﬁn. Sections of
5 μm thickness were subsequently stained with hematoxylin/eosin so-
lution (H&E staining).
8. Results
8.1. Catch-up validation study
8.1.1. Morphological characteristics of the OS-REp model
All epidermal models consisted of 3–5 layers of keratinocytes, re-
vealing the tissue-speciﬁc differentiation pattern (Fig. 4). Palisade-
shaped basal keratinocytes closely adhered to the polycarbonate mem-
brane, followed by cells of the s. spinosum and granulosum, respectively.
At the apical surface a corniﬁed layer had developed. The ET50 values,
which provide an estimation about the barrier function of the OS-REp
models, varied between 2.58 and 9.49 h at day 19 of air-liquid interface
culture for all tissue batches constructed so far at the Henkel laboratory,Fig. 3. Illustration of the experimental setup underlying the physico-chemical analysis of
cross contamination due to volatile chemicals. OS-REp tissues incubated with the
volatile skin-irritating chemical (Iv), with D-PBS only and co-culture inserts ﬁlled with
the adsorbent powder (TENAX) were incubated together in a 6-well plate. After the
indicated periods of time (gray arrow), tissue models, the respective culture media and
the TENAX-ﬁlled inserts were sampled and frozen. The samples were subsequently
subjected to gas chromatography, followed by mass spectroscopy (GC/MS) for physico-
chemical analysis. For each sort of sample a different GC/MS process was used in order
to achieve best resolution.with a mean of 5.66 ± 1.66 h. Based on these historical data an ET50
value of 3.0 h was deﬁned as minimum value for a batch to be qualiﬁed
for phase I of the catch-up validation study. The ET50 values of the 3
batches employed in the validation study were 3.97, 5.97 and 5.96 h,
those for the OS-REp models needed for the additional runs at VITO
and Frankfurt University were 5.38, 4.65 and 3.38 h, respectively.
Thus, all batches were qualiﬁed.
8.1.2. Test acceptance criterion for the negative control (NC)
Tissue viability of PBS-treated OS-REp models was determined with
the MTT assay. In all 3 laboratories the mean optical density was con-
ﬁned to a range from 0.97 to 1.22 units (Fig. 5). All data fell within the
acceptance range of 0.8–1.5 OD units which was deﬁned in the SOP of
the OS-REp SIT based on historical data collected during the develop-
mental phase, and thus all runs clearly fulﬁlled this acceptance criterion.
8.1.3. Test acceptance criterion for the positive control (PC)
In each run 3 tissues were treated with a 5% aqueous SDS solution as
a positive control. The relative tissue viability observed for all runs in allFig. 5. Response of the negative controls (NC) in the three laboratories. Given is the
background-corrected optical density (OD) for each NC tissue replicate in relation to the
experimental run. Horizontal bars indicate the mean OD for each run. All mean OD
values fell within the acceptance range of ≥0.8 and ≤1.5 (dashed lines).
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Thus all runs clearlymatched the acceptance criterion of PC b10%, as de-
ﬁned in the respective SOP and adopted from the OECD Performance
Standards.8.1.4. Variability of the tests
In order to ﬁnd out whether all OS-REp models concurrently tested
with a substance reacted similarly, the standard deviations associated
with the mean values of every single test were analyzed (Table 2).
Only 9 out of 198 tests (i.e. 4.5%), whichwere obtained by the three lab-
oratories in the ﬁrst three runs, revealed standard deviations larger than
18% which is the deﬁned acceptance cut-off value, possibly indicating
towards defect tissue models or inappropriate dosing. Those 9 non-
qualiﬁed tests were repeated in up to 2 additional runs. The SDs of the
re-tests all fulﬁlled the acceptance criterion of SD ≤18% in accordance
with the OECD Performance Standards.8.1.5. Within-laboratory reproducibility (WLR)
The reproducibility of the test performance within each laboratory
was assessed by analyzing theWLR, or concordance, between the inde-
pendent runs. A test result is considered concordant if tissue viabilities
of the 3 valid runs are either all above or all below (or equal) 50% cut-
off value and hence result in the same classiﬁcation. If one run ends
up in a deviating result, the test result is considered discordant. The tis-
sue viabilities for all runs and all chemicals are presented in Table 3 and
in Fig. 7.
In the Henkel laboratory, 17 out of 20 substance treatments were
concordant, resulting in a WLR of 85%. Di-n-propyl disulphide, heptyl
butyrate and 1-bromohexane led to discordant results. The Frankfurt
laboratory reached a concordance of 90%, with di-n-propyl disulphide
and 5% KOH solution leading to discordant results. At the VITO laborato-
ry, only onediscordant resultwas observed after isopropanol treatment,
which equals 95% WLR.Fig. 6. Cell viability of the positive controls (PC) in the three laboratories. Given is the cell
viability (normalized to negative control) for each PC tissue replicate in relation to the
experimental run. Horizontal bars indicate the mean cell viability for each run. All mean
viability values met the acceptance criterion of b10% (dashed line).8.1.6. Between-laboratory reproducibility (BLR)
The BLR was determined by comparing the classiﬁcation results for
every tested substance between all 3 laboratories. The ﬁnal classiﬁca-
tion for a chemical in one laboratory was obtained by calculating the
mean value of relative tissue viability for the 3 valid runs. Fourteen
out of 20 substance treatments gave concordant classiﬁcations (Table
4). Methyl stearate, diethyl phthalate, heptyl butyrate, 1-bromohexane,
isopropanol, and the 5% aqueous solution of potassiumhydroxide led to
discordant classiﬁcations. This study resulted in a 70% BLR, which is
below the deﬁned acceptance criterion of 80%.
8.1.7. Predictive capacity
In order to determine the predictive capacity of the OS-REp-based
skin irritation test, the in vitro classiﬁcation was compared with the in
vivo classiﬁcation according to the GHS system (Table 5). This was
done with contingency tables for every laboratory and for the overall
classiﬁcation. Sensitivity was best at Henkel and VITOwith 100%,mean-
ing that all skin-irritating cat. 2 chemicals were predicted correctly. The
Frankfurt laboratory achieved 80% sensitivity, misclassifying 1-
bromohexane and 5% KOH solution as non-irritants. With an overall
sensitivity of 93% the study met the acceptance criterion of ≥80%. All
laboratories correctly classiﬁed 1-decanol, a so-called borderline chem-
ical (in vivo score 2.3) and di-n-propyl disulphide, a chemical which
gave false-negative results in the validated reference method (VRM).
Speciﬁcity was best at the Frankfurt laboratory with 70%, whereas
Henkel and VITO only achieved 50%. Although Frankfurt met the accep-
tance criterion of 70% speciﬁcity, with 57% the overall speciﬁcity across
the three laboratorieswas too low, strongly suggesting additional inves-
tigations on the false positive chemicals as described below.
The accuracy of 75%, for the single laboratories as well as for the
whole study, met the acceptance criterion of 75% as deﬁned in the
OECD PS (OECD, 2015b).
8.2. Cross contamination
8.2.1. Re-testing of the falsely predicted chemicals
When analyzing the results of the validation study in more detail, it
became evident that in each laboratory different chemicals were
misclassiﬁed: methyl stearate and heptyl butyrate at Henkel, diethyl
phthalate and isopropanol at VITO, and 1-bromohexane and 5% KOH
at Frankfurt, respectively (see above). In order to ﬁnd out whether the
misclassiﬁcation was based on general limitations of the OS-REp SIT,
on mistakes during test performance, or on lab-speciﬁc effects, the 6
chemicals mentioned above were retested in all 3 laboratories. A new
batch of OS-REp models produced at Henkel, whichoriginated from
the same keratinocyte batch as in the validation runs and matched the
quality standards, was used.
Each lab performed one additional skin irritation test with its own 2
misclassiﬁed chemicals including negative and positive controls similar
to the original validation runs on triplicate tissues for every test item. In
addition, VITO and Frankfurt each sent aliquots of their respective
misclassiﬁed chemicals to Henkel, where they were tested on non-
shipped OS-REp models with Henkel's own chemical samples as a
benchmark (Fig. 8).
Henkel as well as VITO now correctly classiﬁed their own 2
chemicals, respectively. In addition, diethyl phthalate and isopropanol
samples from VITO were classiﬁed correctly, too, when tested at the
Henkel lab. The same results were achieved with the Henkel's own
diethyl phthalate and isopropanol samples. All 4 chemicals are non-irri-
tating according to the Draize test, and in all cases the OS-REp models
treated with these substances retained high viabilities with SDs b 18%.
The brominated alkane 1-bromohexane was classiﬁed as a non-irri-
tant at the Frankfurt and theHenkel laboratory, irrespective of its in vivo
score of 2.7 (irritant; OECD, 2015b). The strongly irritating substance 5%
KOH was correctly predicted at the Henkel lab with its own sample as
well as with the sample delivered from the Frankfurt lab. However,
Table 2
Standard deviations (SD) of the normalized tissue viability [%] for all substance exposures and all runs in the 3 laboratories. Included are the SD values for the negative (NC) and positive
(PC) controls. SD values which did not meet the PS acceptance criterion of ≤18% are highlighted in gray.
Test substance Henkel University Frankfurt VITO
No. Name Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 Run 4 Run 5 Run 1 Run 2 Run 3 Run 4
NC PBS 4.4 2.5 10.3 2.7 4.3 7.1 6.4 5.5 5.4 10.3 5.7 5.1
PC SDS (5% aq.) 0.1 0.3 0.4 0.1 0.1 0.1 0.1 0.6 0.1 0.1 0.2 0.1
1 Methyl stearate 11.6 14.7 16.6 8.6 2.0 4.9 – – 11.9 3.3 9.9 –
2 Di-n-propyl disulphide 9.3 7.9 14.7 17.6 30.7 22.4 3.4 0.3 7.7 2.5 3.7 –
3 Hexyl salicylate 1.5 3.2 8.5 4.6 5.2 9.5 – – 14.6 10.0 5.0 –
4 Heptanal 1.0 0.6 0.5 0.4 0.3 0.6 – – 0.4 0.2 0.4 –
5 Diethyl phthalate 11.8 5.4 6.7 9.5 14.8 8.1 – – 1.7 0.4 0.3 –
6 Heptyl butyrate 11.8 15.2 16.8 15.5 3.8 13.9 – – 6.5 7.1 13.0 –
7 1-Bromohexane 8.1 4.2 8.6 10.0 25.1 23.9 7.6 4.2 27.0 1.0 4.8 2.6
8 Naphthalene acetic acid 4.8 5.9 4.5 7.3 19.9 4.2 2.3 – 15.3 8.6 9.3 –
9 Allyl phenoxy-acetate 8.2 13.1 7.5 10.9 7.0 10.6 – – 8.7 7.1 12.8 –
10 4-Methyl-thio-benzaldehyde 0.3 4.3 8.4 15.6 12.1 0.8 – – 0.5 5.8 4.1 –
11 1-Bromo-4-chlorobutane 4.6 0.5 10.0 1.2 2.3 37.3 – 5.3 1.1 3.3 1.7 –
12 Isopropanol 1.9 7.7 6.2 2.2 5.9 2.4 – – 23.9 7.3 4.0 2.6
13 1-Decanol 0.5 0.9 0.8 5.1 0.1 0.4 – – 7.5 0.4 0.2 –
14 Potassium hydroxide (5% aq.) 0.4 4.8 0.1 11.1 11.7 18.5 – 0.5 0.2 0.7 1.0 –
15 1-Methyl-3-phenylpiperazine 0.5 1.1 0.3 2.5 2.9 2.8 – – 0.2 0.8 0.5 –
16 2-Chloromethyl-4-methoxy-3,5-dimethylpyridine HCl 0.5 0.9 0.5 0.3 0.1 0.3 – – 0.3 0.2 0.1 –
17 Cinnamaldehyde 0.2 0.1 0.2 0.2 0.5 0.3 – – 0.5 0.4 0.3 –
18 2-Methyl-5-tert-butylthiophenol 1.8 1.1 0.9 1.4 0.8 0.7 – – 1.7 2.5 2.8 –
19 Tetrachloroethylene 1.2 0.0 5.2 3.9 11.5 4.0 – – 7.3 1.3 5.5 –
20 Cyclamen aldehyde 0.0 0.1 0.1 0.3 0.2 0.3 – – 0.1 0.1 0.4 –
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lab (81% rel. viability).
8.2.2. Biological analysis of cross contamination
These results, together with a thorough investigation of the experi-
mental conditions during the validation runs provided evidence that
the test results in the study were negatively inﬂuenced by the volatile
fractions of skin-irritating substances, especially heptanal and cyclamen
aldehyde, which had been tested in parallel with a non-irritatingTable 3
Tissue viability (% of NC) of the individual runs at the 3 laboratories. Gray highlighted values ind
runs is revealed.
Test substance Henkel Unive
Mean
No. Name Run 1 Run 2 Run 3
(3 valid 
runs) Run 
1 Methyl stearate 41.8 43.1 45.0 43.3 98.2
2 Di-n-propyl disulphide 52.2 28.6 57.6 46.2 22.3
3 Hexyl salicylate 94.9 91.5 100.3 95.6 100.2
4 Heptanal 2.1 2.3 3.7 2.7 2.2
5 Diethyl phthalate 79.4 80.6 95.3 85.1 95.2
6 Heptyl butyrate 43.8 61.3 38.8 48.0 73.0
7 1-Bromohexane 67.2 13.9 25.4 35.5 71.6
8 Naphthalene acetic acid 94.0 89.1 108.0 97.0 97.8
9 Allyl phenoxy-acetate 52.0 57.5 61.4 57.0 89.3
10 4-Methyl-thio-benzaldehyde 1.7 11.8 15.6 9.7 16.2
11 1-Bromo-4-chlorobutane 7.1 0.8 10.1 6.0 12.4
12 Isopropanol 100.2 99.2 102.8 100.8 87.4
13 1-Decanol 1.7 1.9 2.9 2.2 4.4
14 Potassium hydroxide (5% aq.) 1.3 9.0 1.7 4.0 57.1
15 1-Methyl-3-phenylpiperazine 2.7 2.2 2.9 2.6 3.4
16 2-Chloromethyl-4-methoxy-3,5-dimethylpyridine HCl 1.4 1.0 2.0 1.5 0.7
17 Cinnamaldehyde 1.2 0.1 2.8 1.4 1.8
18 2-Methyl-5-tert-butylthiophenol 10.9 4.5 4.4 6.6 4.5
19 Tetrachloroethylene 2.1 1.1 27.9 10.4 40.6
20 Cyclamen aldehyde 1.1 0.3 2.7 1.4 1.0chemical at the same time in the same culture plate. Although the
vapor pressure of the concerned irritating chemicals are quite low it
was concluded that under the given experimental conditions small
amounts of the substances evaporated from the surface of the tissues
and reached the tissues in the neighbouring wells of the same plates
by diffusion via the air phase (cross contamination). It seemed that
even low concentrations of said chemicals may be sufﬁcient to damage
the tissue equivalents irreversibly, resulting in false positive predictions
for the non-irritating chemicals tested in parallel. Each laboratory facedicate non-valid runs with an SD ≤18%. Additionally themean tissue viability of the 3 valid
rsity Frankfurt VITO
Mean Mean
1 Run 2 Run 3 Run 4 Run 5
(3 valid 
runs) Run 1 Run 2 Run 3 Run 4
(3 valid 
runs)
107.5 98.0 – – 101.2 106.5 92.9 80.5 – 93.3
52.1 28.7 98.8 12.7 44.6 26.1 8.8 6.5 – 13.8
103.8 90.8 – – 98.3 117.1 110.3 88.7 – 105.3
2.9 2.6 – – 2.6 2.7 3.0 2.8 – 2.8
104.0 89.2 – – 96.1 2.3 2.0 2.4 – 2.2
84.0 71.1 – – 76.1 96.6 84.6 98.0 – 93.1
80.5 46.9 75.8 86.2 77.9 68.8 6.9 10.4 27.9 15.1
97.5 92.5 98.5 – 96.3 109.7 119.4 94.4 – 107.8
99.7 92.1 – – 93.7 83.2 104.2 75.3 – 87.6
22.4 3.2 – – 13.9 4.0 15.2 8.9 – 9.4
22.7 32.2 – 7.3 14.1 2.5 4.6 3.5 – 3.6
103.7 93.7 – – 94.9 46.9 28.8 27.0 88.2 48.0
1.7 1.8 – – 2.6 6.3 2.4 1.9 – 3.5
49.0 37.6 – 68.7 58.3 1.3 2.1 1.8 – 1.8
3.3 2.5 – – 3.1 1.1 2.1 1.1 – 1.5
1.2 0.8 – – 0.9 0.9 1.3 1.1 – 1.1
2.9 2.0 – – 2.2 2.4 3.7 2.7 – 2.9
4.0 3.9 – – 4.1 6.3 11.2 10.0 – 9.2
19.8 6.5 – – 22.3 37.2 3.5 5.2 – 15.3
2.0 1.1 – – 1.4 1.9 2.3 2.5 – 2.3
Fig. 7.Multipanel conditional display of the cell viability. The mean cell viability (circle symbols) of each valid run is plotted against the laboratory for all 20 test substances. Vertical solid
lines refer to the three valid runs. The horizontal dashed line at 50% viability represents the cut-off value for the prediction of non-irritant No-Category substances (N50%) and irritant
Category-2 substances (≤50%). The in vivo classiﬁcation of the substances is indicated by strip backgrounds in white (non-irritants) and gray (irritants).
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differently for each laboratory and thus were tested in different
combinations.
In order to support the above outlined hypothesis of cross contami-
nation due to volatile irritating chemicals, 2 additional analyses, one
looking again at tissue viability, and one based on gas chromato-
graphical methods, were performed. A biological approach (viability
assay) was conducted in 2 independent experiments with a new
batch of OS-REp models at the Henkel laboratory, which recapitulated
the experimental conditions at the beginning of the catch-up validation
study. OS-REp models treated with the 4 misclassiﬁed non-irritatingchemicalswere confrontedwithmodels treatedwith the respective vol-
atile irritating substances in the same culture plate, followed by viability
assessment. Also models were treated with the misclassiﬁed non-irri-
tants in individual culture plates only and subsequently analyzed in re-
spect of tissue viability.
Treating the tissue models with either heptanal or cyclamen alde-
hyde for the indicated period of time reduced its viabilities to values
of b2% of the negative control, indicating towards completely killed tis-
sues (Fig. 9). The viabilities of tissues treated with methylstearate and
diethylphthalate clearly depended on the culture conditions. When
the tissues were cultivated in one 6-well plate for a single substance
Table 4
Predictive capacity of the OS-REp model. Given is the (ﬁnal) classiﬁcation of each test substance for the laboratories HENKEL, University Frankfurt, and VITO. Additionally given is the in
vivo classiﬁcation according to the UNGHS system aswell as the in vitro classiﬁcation of the Validated ReferenceMethod (VRM; Spielmann et al., 2007; OECD, 2015a). NI: non-irritant (No
Category); Cat. 2: irritant (Category 2). The last column indicates the concordance between the3 laboratories (yes: concordant results, no: discordant results).Whiteﬁelds: classiﬁcation as
no category; gray ﬁelds: classiﬁcation as category 2.
No. Chemical Name GHS in  
vivo
Henkel Univers. 
Frankfurt
VITO VRM in 
vitro
Concordance
1 Methyl stearate No Cat. Cat. 2 NI NI NI no
2 Di–n–propyl disulphide Cat. 2 Cat. 2 Cat. 2 Cat. 2 NI yes
3 Hexyl salicylate No Cat. NI NI NI NI yes
4 Heptanal Cat. 2 Cat. 2 Cat. 2 Cat. 2 Cat. 2 yes
5 Diethyl phthalate No Cat. NI NI Cat. 2 NI no
6 Heptyl butyrate No Cat. Cat. 2 NI NI NI no
7 1–Bromohexane Cat. 2 Cat. 2 NI Cat. 2 Cat. 2 no
8 Naphthalene acetic acid No Cat. NI NI NI NI yes
9 Allyl phenoxy–acetate No Cat. NI NI NI NI yes
10 4–Methyl–thio–benzaldehyde No Cat. Cat. 2 Cat. 2 Cat. 2 Cat. 2 yes
11 1–Bromo–4–chlorobutane No Cat. Cat. 2 Cat. 2 Cat. 2 Cat. 2 yes
12 Isopropanol No Cat. NI NI Cat. 2 NI no
13 1–Decanol Cat. 2 Cat. 2 Cat. 2 Cat. 2 Cat. 2 yes
14 Potassium hydroxide (5% aq.) Cat. 2 Cat. 2 NI Cat. 2 Cat. 2 no
15 1–Methyl–3–phenylpiperazine Cat. 2 Cat. 2 Cat. 2 Cat. 2 Cat. 2 yes
16
2–Chloromethyl–4–methoxy–
3,5–dimethylpyridine HCl
Cat. 2 Cat. 2 Cat. 2 Cat. 2 Cat. 2 yes
17 Cinnamaldehyde No Cat. Cat. 2 Cat. 2 Cat. 2 Cat. 2 yes
18
2–Methyl–5–tert–
butylthiophenol
Cat. 2 Cat. 2 Cat. 2 Cat. 2 Cat. 2 yes
19 Tetrachloroethylene Cat. 2 Cat. 2 Cat. 2 Cat. 2 Cat. 2 yes
20 Cyclamen aldehyde Cat. 2 Cat. 2 Cat. 2 Cat. 2 Cat. 2 yes
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both substances. According to the underlying prediction model these
chemicals were unambiguously classiﬁed as non-irritants.
However, the situation changedwhen themodels treatedwith these
non-irritating chemicals were cultivated together with heptanal-Table 5
Summary of the laboratory-speciﬁc and the overall predictive capacity of the OS-REp SIT
according to the GHS classiﬁcation system, based on 3 valid test runs each. The ﬁelds
highlighted in light gray indicate those parameters which did not match the OECD 439
Performance Standards (OECD, 2015b).
Test laboratory Henkel University 
Frankfurt
VITO All
Sensitivity [%] 100 80 100 93
Specificity [%] 50 70 50 57
Accuracy [%] 75 75 75 75
No. of chemicals 20 20 20 60treated models in the same 6-well plate. The mean viability of the
methylstearate-treated models decreased to 48% of NC, tissue viabil-
ity of the diethylphthalate-treated models even dropped to 17% of
NC only.
The mean viabilities of the tissues covered with heptylbutyrate and
isopropanol and cultured in individual 6-well plates reached 72% and
100% of NC, respectively. Thus bothwere correctly classiﬁed as non-irri-
tants. Cultivating tissue models treated with heptylbutyrate and
isopropanol in a 6-well plate together with cyclamen aldehyde-treated
models elicited no visible effect in this study.8.2.3. Physico-chemical analysis of cross contamination
Aphysico-chemical analytical approachwas designed in order to de-
tect small quantities of heptanal and cyclamen aldehyde in affected
neighbouring OS-REp models. The method relied on the dynamic head-
space analysis, followed by a coupled GC/MS detection, which is able to
detect small organic molecules.
Fig. 8.Results of the repeated skin irritation tests with the falsely classiﬁed chemicals after
protocol optimization. Relative viabilities of the OS-REp models topically treated with the
substances indicated in the diagrams. The tissue models were incubated with 25 μL of
substance each for 35 min and post-incubated for 42 h at 37 °C. Viability was
determined with the MTT assay. The PBS-treated negative controls (NC) are set as 100%
viability, all other data are calculated relative to the NC. Positive controls: tissues treated
with 5% SDS solution. Tests were performed either with the Henkel reference chemicals
(RC) at Henkel, the VITO and Frankfurt RC at the respective labs (VITO, Frankfurt) or the
VITO and Frankfurt RC at the Henkel lab (VITO or Frankfurt at Henkel, respectively).
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Heptanal accumulated in theD-PBS-treated receptor OS-REpmodels
fromnot detectable amounts at the beginning of the exposure period up
to 90 and 120 ng, respectively, measured after 35min. The highest accu-
mulation was seen in the tissues 24 h after the test substance had beenwashed away from the treated models, reaching values of N200 ng/tis-
sue. At the end of the post-treatment incubation period, after 42 h, the
amount of heptanal had decreased to values of 70 and 140 ng/tissue, re-
spectively; Table 6).
Interestingly, parallel to the accumulation of heptanal, also heptanol
(CAS-No. 111-70-6), the reduced form of heptanal, was identiﬁed in the
untreated samples, exceeding the amount per tissue found for the orig-
inal aldehyde. Even after 35 min of incubation values were found with
peak heights beyond the detector limit (200 ng), and according to the
peak width heptanol enrichment proceeded throughout the whole cul-
ture period.
Heptanal rapidly accumulated in TENAX, an adsorbent powder
which had been placed in the 6-well plate, too. Only after 15 min of tis-
sue exposure heptanal levels exceeded the upper limit of the detection
system, and after 24 h post-treatment incubation its amount could be
assumed to be in the microgram range. Heptanol was absent in
TENAX. No heptanal could be detected in the culture medium from un-
derneath the tissue models.
8.4. Cyclamen aldehyde (CyA)
Cyclamen aldehyde in the D-PBS-treated receptor OS-REp models
was detected ﬁrst after 35 min of exposure, reaching values of 3 and
30 ng/tissue, respectively. Throughout the post-treatment incubation
period the aldehyde level in the tissue remained constant at a quite
low level (3–7 ng/tissue). Already after 15 min of cultivation cyclamen
alcohol (CAS-No. 4756-19-8), the reduced form of cyclamen aldehyde,
could be detected in the receptor models, reaching levels between 80
and N200 ng/tissue, respectively. Alcohol amounts of N200 ng/tissue
were observed after 35 min and, after removal of the remaining alde-
hyde on the treated models, during the whole post-treatment incuba-
tion period. Cyclamen aldehyde also accumulated in TENAX, which
had been placed in the 6-well plate. After 35 min of tissue exposure
the aldehyde reached levels of 50 and 100 ng/sample, respectively.
Throughout the whole post-treatment incubation period the amount
of CyA in the adsorbent powder could be assumed to be in the micro-
gram range, according to the peak width. The reduced form, cyclamen
alcohol, was not found in TENAX. No cyclamen aldehyde could be de-
tected in the culture medium, which had been sampled from under-
neath the tissue models.
8.4.1. Recalculation of predictive capacity
The biological analysis revealed that those 4 chemicals which had
been classiﬁed false-positive in the original test series were predicted
correctly as non-irritants when they were tested without any possible
interference with volatile skin-irritating compounds, conﬁrming that
the misclassiﬁcation was not inherent to the OS-REp models, but to an
experimental detail. Since apart from separating the tissues during incu-
bation to avoid cross-contamination, no procedural detail of the testing
protocol had been changed in this special additional re-testing exercise
of a sub-set of chemicals, we decided to merge the supplementary data
for diethylphthalate, methylstearate, heptylbutyrate and isopropanol
with the original dataand to recalculate the predictive performance pa-
rameters for the OS-REp SIT catch-up validation study.While the overall
sensitivity remained unchanged at 93% (80/100/100%), the overall
speciﬁcity increased to 70% (70/70/70%) as required by the OECD PS
(OECD, 2015b), and the accuracy increased to82% (75/85/85%). The
recalculated predictive parameters are presented in Table 7.
9. Discussion
The catch-up validation study presented here was conducted ac-
cording to the rules depicted in the OECD Performance Standards
(2015b). These standards provide a guideline for developers of me-too
methods for in vitro skin irritation testing based on human reconstruct-
ed epidermal models. Derived from the Validated Reference Methods
Fig. 9.Results of the biological cross contamination analysis. OS-REpmodels treatedwith a volatile irritant and a non-irritant (with thepotentially interfering irritant indicated in brackets),
respectively, were cultured together in a 6-well plate. OS-REp models treated with the non-irritating chemicals only were cultured in separate plates. The columns represent the mean
relative viabilities of 3 OS-REp models ± SD, expressed as % of the negative control.
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test method components, a minimum list of reference chemicals to be
tested, and deﬁned reliability and accuracy values.
For the OS-REp model production the protocol for epidermal model
culture, published ﬁrst by Poumay et al. (2004), was modiﬁed in order
to enhance tissue quality and lifespan of the tissue equivalents. Instead
of adult skin, juvenile foreskin was used for keratinocyte isolation, the
culture medium was supplemented with keratinocyte growth factor
(KGF), a member of the ﬁbroblast growth factor family, and the period
of time in which the tissues were cultured at the air-liquid interface
was extended up to 19 days before they are used in the skin irritation
test.
KGF supplementation resulted in increased tissue thickness due to a
higher number of viable keratinocyte layers compared to KGF-free cul-
ture conditions. Thus the OS-REp architecture resembled more closely
that of native human skin. KGFhas been shown tomodulate proliferation
and differentiation of keratinocytes in a 3D human skinmodel grown on
decellularizeddermis (Andreadis et al., 2001) and also to enhancemigra-
tion and hyaluronan synthesis in rat epidermal keratinocytes (Karvinen
et al., 2003). In both studies delayed or even inhibited expression of
cytokeratin 10 (CK10), an early marker of epithelial differentiation
(Stark et al., 1999), was observed. Therefore delayed CK10 expression
is a clear indicator for a prolonged proliferative state on the one handTable 6
Results of the physico-chemical analysis of cross contamination. The numbers represent
the amounts of chemicals identiﬁed in each sample: OS-REp + chemical: concentration
of indicated chemical in untreated tissuemodels; TENAX+ chemical: concentration of in-
dicated chemical in TENAX adsorber powder (ng/sample). CyA/OH: cyclamen aldehyde/
alcohol. N–⋙: beyond the upper detection limit of the GC/MS devices.
Time OS-REp OS-REp TENAX OS-REp OS-REp TENAX
Heptanal Heptanol Heptanal CyA CyOH CyA
0′ b1 b1 b1 b1 b1 b1
15′ 4 15 3 b1 b1 3
15′ 4 40 ≫200 b1 b1 2
35′ 90 N200 ≫200 3 80 50
35′ 120 N200 ≫200 30 N200 100
24 h 200 ≫200 ⋙200 7 N200 ⋙200
24 h N200 ≫200 ⋙200 3 N200 ⋙200
42 h 140 ≫200 ⋙200 5 N200 ⋙200
42 h 70 ≫200 ⋙200 4 N200 ⋙200and for a delayed or compromised terminal differentiation of the
keratinocytes on the other hand, which coincides with increased tissue
thickness and prolonged lifespan of the OS-REpmodel. KGF also exhibit-
ed growth-stimulating effects in reconstituted human oral epitheliumby
increasing the rate of proliferating keratinocyteswithout inﬂuencing ter-
minal differentiation (Costea et al., 2003).
The OECD Performance Standards (2015b) deﬁne the experimental
set-up which was successfully applied in the validated reference
methods with the EpiSkin™ and the EpiDerm™models as a blueprint
for the development of any me-too method for in vitro skin irritation
testing. However, a certain degree of freedom in deﬁning the range of
values for different quality-related parameters is foreseen in the PS, tak-
ing into account the speciﬁc inherent morphological and physiological
properties of reconstructed epidermal models of different origin. For
the OS-REp SIT the exposure time and temperature aswell as thewash-
ing procedure was adapted in order to maximize reliability and
predictivity of our test system.
The OS-REp SIT phase I catch-up validation study, simultaneously
conducted in 3 independent laboratories with 3 batches of OS-REp
models produced independently at Henkel, fulﬁlled the OECD study ac-
ceptance criteria,meaning that for every test chemical and every labora-
tory complete run sequences were generated, which allowed a sound
data analysis.
In the ﬁrst instance, not all reliability and accuracy values were met.
One out of 3 laboratories missed the ≥90% threshold for within-labora-
tory reproducibility, and the between-laboratory reproducibilityof 70%Table 7
Summary of the laboratory-speciﬁc and the overall predictive capacity of the OS-REp SIT
according to the GHS classiﬁcation system. The values have been recalculated on the basis
of the results which were achieved after having solved the cross-contamination issue due
to volatile irritating substances within the reference chemicals panel. All parameters
matched or exceeded the OECD 439 Performance Standards (OECD, 2015b).
Test laboratory Henkel
University 
Frankfurt
VITO All
Sensitivity [%] 100 80 100 93
Specificity [%] 70 70 70 70
Accuracy [%] 85 75 85 82
No. of chemicals 20 20 20 60
250 K.R. Mewes et al. / Toxicology in Vitro 36 (2016) 238–253was clearly below the acceptance criterion of ≥80%.While sensitivity al-
ways fulﬁlled the acceptance criterion of 80%, in two laboratories only
50% speciﬁcity was achieved and thus failed expectations. Interestingly,
each of the three laboratories contributed exactly 2 different chemicals
to the sum of 6 discordantly predicted substances, which included 4
non-irritating, but falsely positive classiﬁed chemicals, and 2 skin-irri-
tating agents, which were classiﬁed as non-irritants. This observation
eventually resulted in a series of additional experiments and analyses
discussed in the chapter below.
With an overall sensitivity of 93% the PS acceptance criterion of ≥80%
was clearly met. Only themisclassiﬁcation of 2 chemicals in one labora-
tory prevented a 100% correct prediction of the skin-irritating
chemicals. It should be mentioned that all laboratories correctly classi-
ﬁed 1-decanol (a borderline chemical) and di-n-propyl disulphide, a
false negative of the validated reference method, which both were irri-
tant in the rabbit test, but non-irritant in the human patch test
(Basketter et al., 2004, 2012; Jírová et al., 2010; EURL-ECVAM, 2009a,
2009b).
In order to achieve more insight into the possible reasons for the
misclassiﬁcations of distinct chemicals in the study laboratories, the re-
sults were analyzed inmore detail. Impaired tissue models could be ex-
cluded as a possible culprit as all OS-REpmodels used in this studywere
produced at Henkel, quality-checked, and then shipped to the study
partners, making sure that every partner received tissues from the
sameproduction lot. Hence, itwould have been plausible in terms of tis-
sue conditions if all partners had misclassiﬁed the same chemicals.
However, this explanation failed in view of the actual test results.
A thorough investigation of the experimental conditions during the
validation runs provided convincing evidence that some test results in
the study were negatively inﬂuenced by the volatile fractions of some
skin-irritating reference chemicals, especially heptanal and cyclamen
aldehyde. They had been tested together with non-irritating chemicals
in the same culture plate according to our initial SOP. Although the
vapor pressures of the concerned irritating chemicals are quite low
(e.g. http://echa.europa.eu/) we hypothesized that under the given ex-
perimental conditions, especially culture of the treated tissue models
at 37 °C, small amounts of the irritant substances evaporated from the
surface of the these tissues and eventually reached the tissues in the
neighbouring wells of the same plates via diffusion. In order to support
the above outlined hypothesis of cross contamination due to volatile ir-
ritating chemicals, we designed an analytical approach, using GC/MS
methods, to detect even small quantities of heptanal and cyclamen alde-
hyde in affected neighbouring OS-REp models. Additionally a biological
approach was chosen in 2 independent experiments which recapitulat-
ed the experimental situation being prevalent during the catch-up val-
idation study.
The time course of aldehyde accumulation in both the tissue equiv-
alents and the TENAX adsorbent powder is indicative of the dynamic
within the culture plates. It can be assumed that already shortly after
starting the tissue incubation with the volatile compounds the whole
space of the 6-well plate was ﬁlled with the respective molecules. Cer-
tainly aldehyde evaporation was facilitated by the incubation tempera-
ture of 37 °C. Thus, under the given test and cultivation conditions, the
aldehydes rapidly accumulated in the neighbouring receptor tissue
equivalents via diffusion. Unexpectedly, even after the donor tissues
had been thoroughly rinsed and placed in the 6-well plate again, alde-
hyde accumulation in the receptor models continued, leading to even
higher aldehyde levels during the post-treatment incubation period.
This observation can be explained only if we assume that the donor tis-
sues becamemassively impregnatedwith the neat chemicals during the
exposure period. Even after removal of the substances from the tissue
surface the molecules then gradually evaporated from the inner part
of the tissues in the course of the post-treatment incubation period,
boosted by the culture temperature of 37 °C.
The accumulation rate of heptanal in the receptormodelswas higher
compared to that of cyclamen aldehyde. This result can be presumablyattributed to differences in vapor pressure and ﬂash point, which both
point at heptanal as the more volatile agent (e.g. http://echa.europa.eu/).
It also became evident that both aldehydes were metabolically
reduced into their respective alcohols within the epidermal tissues.
This is a clear indication for at least basal metabolic activity of the
keratinocytes at the beginning of the post-treatment incubation period,
as far as the cells were not yet irreversibly damaged. In the inert TENAX
adsorber material, the aldehydes accumulated over time to extremely
high values. However, due to the lack of any metabolic capacity of the
adsorbent no reduction into their alcohols or other metabolites occurred.
With the biological approach the immediate toxic effect of volatile
heptanal on juxtaposed tissue models could be demonstrated, ﬁnally
proving the correctness of our hypothesis. In contrast to heptanal, in
this approach cyclamen aldehydewas inconspicuous in respect of dam-
aging neighbouring epidermal equivalents, although this chemical,
when applied topically, led to massively decreased viabilities of the re-
spective tissue. The question why in our experiment the massive accu-
mulation of cyclamen aldehyde according to GC/MS analysis did not
also result in the expected viability decrease remains open at that point.
However, when tested alone in a culture plate and protected from
any possibly interfering volatile irritants, all 4 previously falsely classi-
ﬁed non-irritants were predicted correctly. The observation that in dif-
ferent laboratories different chemicals were falsely classiﬁed can be
considered a consequence of the double-blind coding of the reference
chemicals. As the chemicals samples were coded differently for every
laboratory, they were tested in different orders and hence in different
pairwise combinations on the 6-well plate, too.
To prevent cross contamination and thus misclassiﬁcation of
chemicals due to volatile irritating chemicals in the atmosphere of the
test plate, we highly recommend precautionarymeasures which should
be implemented in SOPs, Performance Standards and the OECD TG 439.
First of all it should be guaranteed that a single substance is tested in
a single 6-well plate only. Special care should be taken regarding the
D-PBS-treated negative controls, too. Any cross contamination must
be avoided e.g. by placing them far away from any volatile substances
in the incubator or even in a separate device. Only then the
uncompromised maximum tissue viability can be determined, which,
because this value is deﬁned as 100% relative viability, inﬂuences all
other results in a given test. Covering or sealing the 6-well plates with
a plastic ﬁlm cannot be recommended throughout the whole test peri-
od. While it might work during the 35 min of incubation time to with-
hold toxic vapors, sealing the tissue models for 42 h is inadequate,
possibly leading to unpredictable culture conditions in the vessel. The
above-mentioned recommendations were adopted in the latest version
of the respective SOP, which was the basis for the second phase of the
OS-REp SIT catch-up validation study (Groeber et al., 2016-in this
volume).
In addition the recent ﬁndings should ignite a discussion about the
question whether those 20 substances stipulated by the OECD TG439
are the best, in respect of their physico-chemical properties, to reliably
validate new in vitro skin irritation tests. Although cyclamen aldehyde
and heptanal, together with the other reference chemicals (RC), were
considered non-volatile when the RC list was originally deﬁned (Eskes
et al., 2007), our results, but also their use in industry, point into another
direction. Cyclamen aldehyde, for example, serves as a fragrance in a
plethora of cosmetic and household products which requires a certain
degree of volatility (http://en.wikipedia.org/wiki/Cyclamen_aldehyde).
Heptanal, as a precursor of perfume components, is already described
as a bad-smelling chemical in publicly available databases (http://en.
wikipedia.org/wiki/Heptanal),which again indicates at its volatile prop-
erty. Thus, in order to avoid any of the above mentioned side effects
when conducting a catch-up validation study, especially the physical
properties of the RCs like vapor pressure and ﬂash point should be thor-
oughly revised and eventually critical chemicals replaced.
On the other hand the analysis of cross contamination presented in
this work might open the door to testing gaseous chemicals and
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ident that epidermal equivalents exposed to gaseous chemicals only via
diffusion in a lid-covered 6-well plate reacted similarly to equivalents
treated directly with the respective liquids. Thus, one could imagine a
quite simple experimental set-up where the skin models and either a
small reservoir of volatile compounds or a deﬁned volume of a gas or
aerosol are enclosed in a vessel under static conditions. To our knowl-
edge no validated method exists so far for testing gases and aerosols
(OECD TG 439, 2015a; OECD Guidance Document No. 203, 2014).
During the catch-up validation study 2 chemicals were classiﬁed
false negative in 1 laboratory, an effect which cannot be explained by
cross contamination as described above. No explanation was found for
5% KOH, because when retested in the other 2 laboratories identical
samples of this highly alkaline solution always reduced the viability to
values below 10% (data not shown). For 1-bromohexane (1-BH) the sit-
uation appears quite different, and its selection as a reference chemical
bears some unpredictabilities. It was not only tested false negative in 1
laboratory, but also in 1 out of 3 valid runs in a second laboratory.
Other companies faced this problem, too. Straticell (Belgium) has
presented results of a skin irritation study with their own epidermal
model, where 1-bromohexane was not always predicted correctly
(Eeman et al., 2010). In addition, they observed a high degree of vari-
ability in the viability data between the single runs, which could not
be eliminated even after optimizing the testing process. Similar results
were shown in amulticenter study performedby the Japanese company
J-TEC Co. Ltd. with the epidermal model “LabCyte EPI-MODEL24” in
preparation of a catch-up validation study (Katoh et al., 2009; OECD,
2011; Kojima et al., 2014). In the Japanese study 1-BH was predicted
as a non-irritant according to the MTT data, and only after taking sup-
plementary IL1-α release data into account it was considered to be an
irritant. Increasing the volume of test substance did not affect the test
results at all. Raising the temperature to 37 °C during substance treat-
ment resulted in a correct prediction of 1-BH, but other non-irritating
chemicals were predicted false positive instead. Only standardizing
the washing protocol in order to remove chemical remnants from the
tissue surface resulted in sufﬁciently low relative viabilities for a classi-
ﬁcation concordant with the in vivo score. However, it is not obvious
why a more gentle washing procedure lowered tissue viability after
substance application. Any other modiﬁcations revealed no effect re-
garding the 1-BH challenge.
During the EURL-ECVAM validation study 1-BH was misclassiﬁed in
three laboratories when using the EpiDerm™model (Spielmann et al.,
2007). No clear reasonswere provided for themisclassiﬁcation.Misclassi-
ﬁcation of 1-BH as a non-irritant was also recently reported in a skin irri-
tation studywith the KeraSkin™-VMepidermalmodel (Jung et al., 2014).
The varying behaviour of the different epidermal models after 1-
bromohexane treatment conspicuously corresponds with the effects
observed on the native human skin as revealed in a study published
by Jírová et al. (2010). In a 4-h patch test 16 out of 30 test persons exhib-
ited a positive skin irritation reaction (53%), whereas the other 14 test
persons did not show any sign of a reaction. Therefore the chemical
with an in vivo score of 2.7 (OECD, 2015b) must be discussed as a “bor-
derline” substance, of which the reaction cannot be determined unam-
biguously. Based on these data it can be hypothesized that the high
degree of variability seen in the patch test is also mirrored in the tissue
models when they are constructed from cells of different donors. De-
pending on the individual genetic and physiological backgrounds of
their donors, keratinocytes and epidermal models, respectively, will
then react the one or other waywhen confronted with 1-BH. A uniform
reaction cannot be expected on this premise.
Another case of low Draize test -human correlation was revealed
with di-n-propyl disulphide with only 20% of the human volunteers
exhibiting positive reactions (Jírová et al., 2010). Interindividual differ-
ences in the in vivo test and thus high donor variability in epidermal
equivalents are the likely cause for the observed differences in the in
vitro skin irritation tests. Using chemicals, where the skin irritationreaction differs signiﬁcantly between rabbit and men and even within
a human population, as a standard for validation of an in vitro method
must be seen very critically. Especially against the background of the
open source concept, which explicitly allows ﬂexibility in respect of
cell donor origin, these standards can erect massive hurdles on the
way to establish the new method at any laboratory. It must also be
questioned whether a new in vitro method should not better mirror
the human skin physiology rather than the animal situation.
Differences based on the ethnic backgroundof the epidermalmodels
are discussed as a possible reason for misclassiﬁcation, too (Jung et al.,
2014). Taken together these observations should initiate a discussion
about the value of 1-bromohexane and di-n-propyl disulphide as SIT
reference substances. More emphasis should be laid on human data if
they are available for a certain chemical.
After having re-analyzed those chemicals which were falsely pre-
dicted in the ﬁrst instance the predictive capacity of the OS-REp SIT
has been recalculated for each of the participating laboratories, elimi-
nating those discordant results clearly linked to the cross-contamina-
tion effect.
On this premise all laboratories met the EURL-ECVAM acceptance
criteria of ≥80% sensitivity and ≥70% speciﬁcity. Whereas the degree
of sensitivity was not affected by the recalculation, the speciﬁcity was
markedly increased. Only the classiﬁcation for 5% KOH and 1-
bromohexane, both considered skin-irritant according to the Draize
skin test, remained unchanged due to the arguments presented above.
Taken together, the OS-REp SIT method has proven its value to dis-
tinguish non-irritants (below GHS category 2) from skin-irritating sub-
stances (GHS category 2) with high reliability.
With the OS-REp a new epidermal equivalent has been introduced as
a valuable tool to assess the skin irritation potential of chemicals in vitro.
The most recent version of the OECD TG 439 (2015a) lists four commer-
cially available epidermal equivalents which have undergone the com-
plete formal validation process for its use in in vitro skin irritation
testing. Based on the data and experiences achieved during the EpiSkin
™, EpiDerm™ SIT (EPI-200) and SkinEthic™ RHE validation studies, the
so-called Validated Reference Methods (VRM), performance standards
were deﬁned which are mandatory to be matched by newmethods con-
sidered similar to the VRM (me-too methods). They deﬁne the basis for
every catch-up validation study for skin irritation testswith reconstructed
epidermal models (EURL-ECVAM, 2009a, 2009b; OECD, 2015b).
With 74.4% sensitivity and 80.8% speciﬁcity the EpiSkin™ SIT predic-
tive capacity was considered sufﬁciently high in order to endorse this
method as a full replacement of the Draize skin test. According to the
lower sensitivity of 56.3% in the course of the original ECVAM SIVT,
the protocol for the EpiDerm™ SIT was optimized (Kandárová et al.,
2009). Speciﬁcity was then 76.3%, and sensitivity increased to 86.1%
with an overall accuracy of 80.6% for a set of 55 test chemicals, which
qualiﬁed the EpiDerm™ SIT as a stand-alone test, too.
The validation study with the SkinEthic™ RHE model resulted in
90% sensitivity, 80% speciﬁcity and an overall accuracy of 85%
(Alépée et al., 2010). While sensitivity of the OS-REp SIT was even
better, speciﬁcity was lower, which might be attributed to changes
in the reference chemicals list after the SkinEthic™ SIT study had
been conducted.
The list of epidermal models for SIT was only recently complemented
by the LabCyte EPI-MODEL24 SIT (OECD, 2015a). The overall predictive
parameters of the Labcyte catch-up validation study with the optimized
protocol were 70% speciﬁcity, 90–100% sensitivity and 80–85% accuracy
(Kojima et al., 2014). In a skin irritation test carried out with the
KeraSkin™-VM epidermal equivalent following the Performance Stan-
dards 70% speciﬁcity and 80% sensitivity were achieved, too (Jung et al.,
2014).
Thus, the predictive capacity of ourOS-REP SIT is comparablewith or
even better than the already validated skin irritation assays listed above.
On this basis the second tier of the catch-up validation study was orga-
nized, where also OS-REpmodel production was completely conducted
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paper in this journal (Groeber et al., 2016-in this volume).
To our knowledge this is the ﬁrst time that an in vitro skin irritation
test based on the open source concept undergoes a Performance Stan-
dard-driven validation study. The open source concept encompasses
both the production of the respective epidermal equivalent (OS-REp)
and the test performance, which gives any potential user the freedom to
operate independently of commercial or legal restrictions.
As already indicated in the introduction chapter, the open source
concept entered public consciousness ﬁrst as an innovative strategy in
information technology (Nicolosi and Ruivenkamp, 2012). In themean-
time the open source debate has also been opened e.g. in the ﬁelds of
nanotechnology (Frangioni, 2012), drug discovery (Ardal, 2012) and
biomedical technology (Pearce, 2012), both aiming at more ﬂexibility,
transparency, and product availability in the respectivemarkets. The in-
creasing scientiﬁc and public interest in open source concepts is also
mirrored in the rapid increase in the number of open source-related
publications during the last few years (http://www.ncbi.nlm.nih.gov/
pubmed).
Many of the features characterizing the open source concept for soft-
ware can be applied for animal alternatives, too. All underlying proto-
cols and quality criteria for the tissue production as well as for the in
vitro test aremade publicly available without any restrictions. Everyone
will be free and in the legal position to performallworking steps and ex-
periments by his/her own. However, the right to alter the source code,
or, in the case of an in vitro method, the underlying SOP's, must be re-
stricted for the following reasons. In the case of validated and regulatory
accepted tissue models and alternative methods no deviations from the
protocols as well as from the respective quality and performance stan-
dards must be allowed. Any change in the protocols can lead to unex-
pected effects which, in the end, can compromise the reliability and
predictivity of the whole test system. Therefore, once a method has un-
dergone the complete validation and acceptance process, the quality
criteria for tissuemodel production and test performance are mandato-
ry for any user when the test is used in a regulatory framework. Moni-
toring of the quality standards at the production sites/test labs is
recommended on a regular basis.
Nevertheless, the development/optimization of tissue models and
new in vitro test systems are dependent on the active participation of
interested and experienced users and scientists. Only improvements
in the protocols and adaptations of the quality standards will pave the
way to innovation. However, in the end the optimized test method or
tissue model will differ from the original one, for which the validation
had been achieved. Therefore a new validation study or at least a proﬁ-
ciency exercise will be required in order to prove the equivalence of the
new and old test method.
10. Conclusion
Taken together, the OS-REp SIT method presented in this paper
has proven its value to distinguish non-irritants from skin-irritating
substances with high reliability, thereby matching the stipulations of
the respective Performance Standards. The predictive capacity is com-
parable to those achieved with the four test methods listed in the
OECD TG 439 (OECD, 2015a).
The OS-REpmimics anatomical and structural features of the human
epidermis and thus can be employed to predict skin irritation. Several
quality criteria must be met before OS-REp models become qualiﬁed
to be used in the skin irritation assay. Beside those criteria as described
in the Performance Standards (OECD, 2015b) it is of utmost importance
to carefully assess the suitability of the keratinocytes in order to ensure
that the tissue models constructed of these cells have the appropriate
predictive capacity. Only after a proﬁciency exercise with all PS refer-
ence chemicals has been successfully conducted, the open source-
based SIT can be used to test unknown chemicals for their skin-irritating
potential.The test protocol had to be modiﬁed after it became evident that
some of the chemicals were classiﬁed false-positive in the ﬁrst instance,
resulting in a too low overall speciﬁcity. It was proven that some of the
skin-irritating reference chemicals used in the validation study were
volatile and thus able to contaminate and damage tissue models cul-
tured in the same culture vessel or even in the same incubator. When
the non-irritating overpredicted reference chemicals were retested
with the slightly modiﬁed protocol, in which every chemical was tested
in an individual culture vessel, they were all predicted correctly. These
results were then included into the ﬁnal calculation of predictivity.
From these analyses we recommend to implement speciﬁc mea-
sures in order to avoid any cross contamination effects. The tissue
models should be incubated with a single substance in a single 6-well
plate only, and models treated with non-irritants should be kept sepa-
rately from those treated with volatile irritants, at best in separate CO2
incubators, if possible. Negative controls should be kept as far away as
possible from any volatile irritants.
We also highly recommended that thesemeasures should be imple-
mented in SOPs, Performance Standards and the respective OECD test-
ing guideline in order to raise consciousness for challenging physical
properties of the chemicals to be tested and eventually to avoid cross
contamination and thus misclassiﬁcation of chemicals.
A few reference chemicals, especially 1-bromohexane, but also di-n-
propyl disulphide, appear not to be suitable to validate in vitro skin irri-
tation tests due to their poor animal – human correlation and high im-
pact of donor variability on the test outcome. A replacement of these
chemicals in the TG is highly recommended.
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